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doi:10.1016/j.jfma.2010.11.002Background/Purpose: Nuclear localization of b-catenin is known to associate with malignant
transformation of many squamous cell carcinomas. The aim of this study was to compare
b-catenin expression in normal human oral epithelium and areca quid chewing associated oral
squamous cell carcinomas (OSCCs) and further to explore the potential mechanisms that may
lead to induce b-catenin expression.
Methods: A total of 40 areca quid chewing-associated OSCCs and 10 normal oral tissue biopsy
samples without areca quid chewing were analyzed by immunohistochemistry. The oral epithe-
lial cell line GNM cells were challenged with arecoline, a major areca nut alkaloid, by using
Western blot analysis. Furthermore, extracellular signal-regulated protein kinase inhibitor
PD98059, glutathione precursor N-acetyl-L-cysteine (NAC), tyrosine kinase inhibitor
herbimycin-A, p38 inhibitor SB203580, and phosphatidylinositaol 3-kinase inhibitor LY294002
were added to find the possible regulatory mechanisms.
Results: b-catenin expression was significantly higher in OSCC specimens than that in normal
oral epithelial specimens (p < 0.05). It was demonstrated that normal oral epithelium showed
only membranous staining for b-catenin, and membranous staining was lost or reduced with an
increase in cytoplasmic/nuclear staining in OSCCs. Arecoline was found to elevate b-cateninentistry, Chung Shan Medical University, 110, Section 1, Chien-Kuo N. Road, Taichung, Taiwan.
(Y.-C. Chang).
to the results of this study.
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
b-catenin expression in areca quid chewing associated OSCCs 195expression in a dose-dependent manner (p < 0.05). The addition of PD98059, NAC, herbimycin-
A, SB203580, and LY294002 markedly inhibited the arecoline-induced b-catenin expression
(p < 0.05).
Conclusion: b-catenin expression is significantly upregulated in areca quid chewing-associated
OSCC. The localization of b-catenin expression is correlated with the tumor size and clinical
stage. In addition, b-catenin expression induced by arecoline is downregulated by PD98059,
NAC, herbimycin-A, SB203580, and LY294002.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Oral squamous cell carcinoma (OSCC), which accounts for
approximately 90% of oral malignancies, is the eighth most
common cancer in the world.1 The most common etiologies
appear to be related to the oral habit of areca quid chewing,
tobacco smoking, and heavy alcohol consumption.2 Areca
quid is carcinogenic to humans3 and is an independent risk
factor in the development of OSCC among people with
this habit in Southeast Asia.4,5 However, the pathogenesis
of areca quid chewing-associated OSCC remains to be
elucidated.
b-catenin, a cytoplasmic protein, is often involved in the
regulation of E-cadherin-mediated cell adhesion and in the
Wingless/Wnt signaling pathway.6 It plays an important role
in the maintenance of epithelial structure with other
members of the E-cadherin/catenin complex.7 In normal
epithelial cells, in the absence of a Wnt signal, free cyto-
plasmic b-catenin interacts with the adenomatous polyposis
coli (APC) tumor-suppressor protein and is phosphorylated by
glycogen synthase kinase-3b at serine/threonine residues,
which are encoded in exon 3 of the b-catenin gene.8,9 One of
the hallmarks of activated Wnt signaling is the accumulation
of nuclear b-catenin,10 a downstream component of the Wnt
signaling pathway. Nuclear localization of b-catenin is known
to be associated with the malignant transformation of
squamous cell carcinoma of the esophagus, adenocarcinoma
of the stomach, and adenocarcinoma of the colon.11,12 In
addition, reduced cell adhesive properties of this complex
have been reported to be associated with tumor develop-
ment and progression in OSCCs.13e16
Recently, nuclear b-catenin was found to be correlated
with the tumor malignancy index in Taiwanese pop-
ulation.17 Areca quid chewing is a major risk factor in the
development of OSCCs in Taiwan.18 However, there is
limited information on the regulation of b-catenin expres-
sion in areca quid chewing-associated OSCCs both in vitro
and in vivo. The purpose of this study was to test whether
b-catenin expression is regulated in areca quid chewing-
associated OSCC specimens and to further explore the
possible pathogenic mechanisms that may lead to the
induction of b-catenin in vivo. The oral epithelial cell line
GNM cells were challenged with arecoline, the major areca
nut alkaloid, in vitro. Furthermore, extracellular signal-
regulated protein kinase (ERK) inhibitor PD98059, gluta-
thione (GSH) precursor N-acetyl-L-cysteine (NAC), tyrosine
kinase inhibitor herbimycin-A, p38 inhibitor SB203580, and
phosphatidylinositaol 3-kinase (PI3K) inhibitor LY294002
were added to investigate the possible mechanisms and
their protective effects.Materials and methods
Arecoline, NAC, and herbimycin A were purchased from
Sigma (St. Louis, MO, USA). PD098059, SB203580, and
LY294002 were obtained from Promega (Madison, WI, USA).
b-catenin (sc-59737) antibody was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). All culture materials
were obtained from Gibco (Grand Island, NY, USA). The final
concentration of PD098059, NAC, herbimycin-A, SB203580,
and LY294002 used in this study were 10 mM, 1 mM, 10 mM, 26
mM, and 163 mM, respectively.
Immunohistochemistry
Formalin-fixed, paraffin-embedded specimens of 10 normal
oral epithelium specimens from non-areca quid chewers,
and 40 OSCC specimens from areca quid chewers, were
drawn from the files of the Department of Pathology, Chung
Shan Medical University Hospital. Diagnosis was based on
the histological examination of hematoxylin- and eosin-
stained sections. Institutional Review Board permission at
the Chung Shan Medical University Hospital was obtained for
the use of discarded human tissues. Sections (5 mm thick)
from formalin-fixed, paraffin-embedded specimens were
stained with the monoclonal anti-b-catenin antibody (1:50
dilution) using a standard avidinebiotineperoxidase complex
methodas describedpreviously.19 Diaminobenzidine (Zymed,
South San Francisco, CA, USA) was then used as the substrate
for localizing the antibody binding. Negative controls
included serial sections from which either the primary or
secondary antibodies were excluded. The preparations were
counterstained with hematoxylin, mounted with Permount
(Merck, Darmstadt, Germany), and examined using light
microscopy.
Cell culture
The oral epithelial cell line GNM cells,20 derived from
a patient with T2N2aM0 (Ref. No. 0-18353) gingival carci-
noma and metastasis to the cervical lymph node at the
Department of Oral & Maxillofacial Surgery, School of Sto-
matology, Wuhan University, were grown in RPMI 1640
medium supplemented with 10% fetal calf serum (FCS) and
antibiotics (100 units/mL of penicillin, 100 mg/mL of strep-
tomycin, and 0.25 mg/mL of fungizone). Cultures were
maintained at 37C in a humidified atmosphere of 5% CO2 and
95% air. Confluent cells were detached with 0.25% trypsin
and 0.05% EDTA for 5 minutes, and aliquots of separated cells
were subcultured.
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Cells arrested in G0 by serum deprivation (0.5% FCS; 48
hours) were used according to our previous experiment.21
Nearly confluent monolayers of GNM cells were washed
with serum-free medium and immediately thereafter
exposed to 0, 20, 40, 80, and 160 mg/mL arecoline. Cell
lysates were collected after 8 hours for Western blot anal-
ysis. Cultures without FCS were used as negative control.
Subsequently, various pharmacological agents were added
to test their regulation effects during the 8-hour coincuba-
tion period.
Western blot
For Western blot analysis, cell lyates were collected as
described previously.22 Briefly, cells were solubilized with
sodium dodecyl sulfate-solubilization buffer (5 mM EDTA, 1
mM MgCl2, 50 mM TriseHCl, pH 7.5, and 0.5% Trition X-100,
2 mM phenylmethylsulfonyl fluoride, and 1 mM N-ethyl-
maleimide) for 30 minutes on ice. Next, cell lysates were
centrifuged at 12,000  g at 4C and the protein concen-
trations determined with Bradford reagent using bovine
serum albumin as standards. Equivalent amounts of total
protein per sample of cell extracts were run on a 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and immediately transferred to nitrocellulose membranes.
The membranes were blocked with phosphate-buffered
saline containing 3% bovine serum albumin for 2 hours,
rinsed, and then incubated with primary antibodies anti-b-
catenin (1:500) in phosphate-buffered saline containing
0.05% Tween 20 for 2 hours. After three washes with Tween
20 for 10 minutes, the membranes were incubated forFigure 1 (A) Strong membranous expression of b-catenin in the n
(200). (B) Peripheral loss of membranous of b-catenin in well-di
weak or negative b-catenin staining (200). (C) Cytoplasmic and n
samples (200). (D) Absent membranous expression of b-catenin w1 hour with biotinylated secondary antibody diluted 1:1000
in the same buffer, washed again as described above, and
treated with 1:1000 streptavidineperoxidase solution for 30
minutes. After a series of washing steps, protein expression
was detected by chemiluminescence using an ECL detection
kit (Amersham Biosciences UK Limited, England), and
relative photographic density was quantitated by scanning
the photographic negatives on a gel documentation and
analysis system (AlphaImager 2000; Alpha Innotech Corp.,
San Leandro, CA). Each densitometric value was expressed
as the mean  SD.
Statistical analysis
The statistical significance of differences between b-
catenin localization and various clinico-pathologic features
(T-categories, N-categories, age, sex, staging of the patients,
and cell differentiation of OSCC) were assessed using Fisher’s
exact test for independence. For Western blot assay, tripli-
cate separate experiments were performed throughout this
study. The significance of the results obtained from control
and treated groups was statistically analyzed using paired
Student t-test. A p value <0.05 was considered statistically
significant.
Results
b-catenin staining was mainly expressed in the OSCC
specimens, and the intensity was significantly higher than
that in normal epithelial specimens (p < 0.05). As shown in
Fig. 1A, cytoplasmic or nuclear staining of b-catenin was
not detected in all samples examined in the normal oral
epithelium. b-catenin signals were detected in the cellormal oral epithelium, with no cytoplasmic/nuclear expression
fferentiated OSCC, keratin pearls or keratinizing cells showed
uclear staining of b-catenin in moderately differentiated OSCC
as recognized in poor differentiated OSCC (200).
Figure 2 Expression of b-catenin in arecoline-treated GNM
cells by Western blot. Cells were exposed for 8 hours in serum-
free DMEM containing various concentrations of arecoline as
indicated. b-actin was performed in order to monitor equal
protein loading.
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absent in the most superficial layers.
In well-differentiated OSCC, cytoplasmic and nuclear
staining of b-catenin was detected in all samples (Fig. 1B).
In well-differentiated cancer nests, keratin pearls or kera-
tinizing cells showed weak or negative b-catenin staining. In
moderately differentiated OSCC, cytoplasmic and nuclear
staining of b-catenin was detected in all samples (Fig. 1C).
In addition, a significant reduction of membranous staining
was observed. The lack of membranous expression of b-
catenin was observed in poorly differentiatedOSCC (Fig. 1D).
A significant increase in cytoplasmic/nuclear b-catenin
expression was noted. As shown in Table 1, there was no
significant difference in b-catenin expression in the differ-
entiation of OSCC (pZ 0.109)
As shown in Table 1, study participants were divided into
two age groups: greater than or less than the median age
(54 years). The immunostaining localization of b-catenin in
OSCC could be classified into two groups: nuclear, 57.5%
(23/40), and membrane, 42.5% (17/40). No significant
difference in the localization of b-catenin expression was
observed with respect to other factors, such as sex, age,
differentiation, and lymph nodes metastasis (p > 0.05). The
localization of b-catenin expression was significantly asso-
ciated with tumor size (p Z 0.02) and stage (p Z 0.024).
Expression of b-catenin in GNM cells challenged with
arecoline was elevated by Western blot. As shown in
Fig. 2, arecoline was found to elevate b-catenin expression
in a dose-dependent manner (p < 0.05). From theTable 1 Association of clinical features of patients and
immunohistochemical expression of b-catenin.
Clinicopathologic
features
b-catenin expression p
Mem (n Z 17) C/N (n Z 23)
Sex
Male 13 21 0.373
Female 4 2
Age (y)
&54 9 11 1.0
＞54 8 12
Size
&4 cm 15 12 0.02
＞4 cm 2 11
LN involvement
No 14 12 0.092
Yes 3 11
Differentiation
Well 11 8 0.109
Moderate/Poor 6 15
Stage
I þ II 11 6 0.024
III þ IV 6 17
Statistical analysis was performed using Fisher’s exact test. A p
value <0.05 was considered statistically significant.
LN Z lymph node; Mem Z membranous; C/N Z cytoplasmic/
nuclear.AlphaImager 2000 (Fig. 3), the amount of b-catenin was
elevated about 1.1-, 2.2-, 6.0-, and 3.5-fold after exposure
to 20, 40, 80, and 160 mg/mL arecoline (p < 0.05),
respectively. The peak of b-catenin protein level induced
by arecoline was 80 mg/mL. On the basis of these results,
experiments described below were performed at a concen-
tration of 80 mg/mL arecoline.
PD98059, NAC, herbimycin-A, SB203580, and LY294002
without cytotoxic concentrations were added to search for
the possible regulatory mechanisms on arecoline-induced
b-catenin expression. These pharmacological agents were
found to inhibit the arecoline-induced b-catenin expression
(p < 0.05) (Fig. 4). From the AlphaImager 2000 (Fig. 5),
PD98059, NAC, herbimycin-A, SB203580, and LY294002 were
found to reduce the arecoline-induced b-catenin expression
by lowering 2.8-, 2.5-, 4.4-, 4.5-, and 3.6-fold (p < 0.05),
respectively.
Discussion
b-catenin signaling plays a key role in a variety of cellular
contexts during embryonic development and tissue differ-
entiation. Aberrant b-catenin signaling has been implicated
in promoting many human squamous cell carcinomas.11,12Figure 3 Levels of b-catenin protein treatment with areco-
line were measured by densitometer. The relative level of b-
catenin protein expression was normalized against b-actin
signal and the control was set as 1.0. Optical density values
represent the mean  SD. *Significant difference from control
values with p < 0.05.
Figure 4 The regulatory effects of PD098059, NAC,
herbimycin-A, SB203580, and LY294002 on arecoline-induced b-
catenin expression in GNM cells. Cells were coincubation with
various pharmacological agents in the presence of 80 mg/mL
arecoline. b-actin was performed in order to monitor equal
protein loading.
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expression of b-catenin in areca quid chewing-associated
OSCC both in vitro and in vivo. To the best of our knowl-
edge, b-catenin expression was first found to be highly
expressed in areca quid chewing-associated OSCCs as
compared with normal epithelium tissues. Normal oral
epithelium has shown only membranous staining for b-cat-
enin, and membranous staining was lost or reduced with an
increase in cytoplasmic staining in areca quid chewing-
associated OSCCs. Similar results were found in previous
studies: that b-catenin was highly expressed in oral cancer
specimens.13e17 Thus, membranous staining may be lost or
markedly reduced according to the cytoplasmic internali-
zation/nuclear staining of b-catenin in the pathogenesis of
areca quid chewing-associated OSCCs.
The clinical significance of nuclear b-catenin expression
in oral cancer is controversial. b-catenin nuclear stain has
been shown to associate with proliferation, invasiveness,
and worse prognosis of oral cancer.13e17 In the present
study, the important finding is that the nuclear b-catenin
expression has an inverse correlation with tumor size andFigure 5 Quantization of arecoline-induced b-catenin
expression in GNM cells was achieved by densitometer as
described in Fig. 2. *Significant difference from control values
with p < 0.05. #Statistically significant between arecoline
alone and arecoline with pharmacological agents; p < 0.05.clinical stage. However, Gasparoni et al23 reported that
nuclear b-catenin was rare in oral cancer and found no
clear association between intranuclear b-catenin and
histopathological and malignancy indexes in vivo. The
reason for this contrary result is not clear. This may be due
to the different origins of the specimens, different causa-
tion of OSCC, or different experimental protocols used in
each laboratory.
The activation of b-catenin in areca quid chewing-
associated OSCCs may be explained as follows. Cyclin D1
have been identified as target genes of the Wnt/b-catenin
pathway.24 Cyclin D1 nuclear staining was observed to be
highly expressed in areca quid chewing-associated OSCCs in
Taiwan.25 In addition, inactivation of the APC gene results in
accumulation and translocation of b-catenin, which are
important for malignant development.26 APC mutations
were found to contribute to the carcinogenesis of at least
some OSCCs in Taiwan, especially for users of areca quid.27 It
is therefore feasible to suggest that cyclin D1 pathway and/
or APC gene mutation may at least in part be responsible
for the upregulation of b-catenin in areca quid chewing-
associated OSCCs. However, the interaction among b-
catenin, cyclin D1, and APC deserves further investigation.
In this study, we first reported the upregulation of b-
catenin expression in oral epithelial cell line GNM cells
stimulated by arecoline. This suggests that one of the
pathogenic mechanisms of OSCC may be the synthesis of
b-catenin expression by epithelial cells in response to areca
quid challenge.
The ERK signaling pathway is one of the mitogen-
activated protein kinase cascades and plays important
roles in the regulation of cell growth and differentiation.28
Previously, b-catenin was found to be abolished by PD98059
in RK3E cells.29 In this study, PD98059 was found to reduce
b-catenin protein expression by arecoline. In accord, Chang
et al30 reported that areca nut extract treatment resulted
in the significant induction of p-ERK in human oral kerati-
nocytes. These data demonstrate that activation of the
ERK pathway may involve in arecoline-induced b-catenin
expression in GNM cells.
Previously, we demonstrated that arecoline significantly
depletes intracellular GSH in human buccal mucosal fibro-
blasts.31 NAC is easily deacetylated inside the cells and
provides cysteine for cellular GSH synthesis and thus stim-
ulates the cellular GSH system.32 In this study, NAC was
found to inhibit arecoline-stimulated b-catenin expression.
Taken together, GSH may act as an intracellular buffer
against arecoline-mediated b-catenin expression.
Decreased b-catenin phosphorylation was reported to
block cell migration in the tyrosine kinase inhibitor
herbimycin-A in the IEC-6 cell line derived from normal rat
intestine.33 The cell migration rate was decreased by adding
herbimycin A in an oral epithelial cell line derived from
buccal mucosa squamous cell carcinoma, HO-1-N-1.34 In this
study, herbimycin Awas found to inhibit arecoline-stimulated
b-catenin expression. Taken together, activation of the
tyrosine kinase pathway may involve in arecoline-induced b-
catenin expression.
Recently, Bikkavilli et al35 reported a novel role for p38
in canonical Wnt-b-catenin signaling. The p38 inhibitor
SB203580 strongly attenuates the Wnt3a-induced b-catenin
accumulation. The cell migration rate was decreased by
b-catenin expression in areca quid chewing associated OSCCs 199adding SB203580 in HO-1-N-1 cell line.34 In this study, we
also demonstrated that SB203580 inhibited arecoline-
stimulated b-catenin expression, highlighting a critical
role for p38 in b-catenin signaling.
The PI3K consists of regulatory regulatory (p85) and
catalytic (p110) subunits that participate in multiple
cellular processes including cell growth, transformation,
differentiation, and survival.36 Inhibition of PI3K signaling
with LY294002 was reported to decrease nuclear accumu-
lation of b-catenin in prostate cancer cell line LNCaP.37 In
this study, LY294002 was found to reduce b-catenin protein
expression by arecoline. These data demonstrate that
activation of the PI3K pathway may involve in arecoline-
induced b-catenin expression in GNM cells.
This study shows that b-catenin is elevated in OSCC
specimens from areca quid chewers. Arecoline was capable
of stimulating b-catenin expression in GNM cells. This
suggests that areca quid chewing may contribute to the
pathogenesis of OSCCs via b-catenin expression. b-catenin
inhibited by PD98059, herbimycin-A, SB203580, and
LY294002 suggest that ERK, tyrosine kinase, p38, and PI3K
transduction pathways may be involved in the arecoline-
stimulated b-catenin expression. b-catenin inhibited by
NAC indicates that arecoline-stimulated b-catenin expres-
sion may be partially related to the GSH levels. Therefore,
studying the regulatory mechanisms involved in b-catenin
expression may prove versatile. However, more detailed
studies should be undertaken to clarify the areca nut
constitutes that can regulate b-catenin in vitro and in vivo.
The design of in vitro studies cannot explain the decreased
membranous staining and increased nuclear staining of b-
catenin in OSCC samples in vivo. Because the proteins were
extracted from whole cells in the present study, the protein
from nuclear or membrane should be addressed separately
in further studies to clarify the actual mechanism of b-
catenin nuclear translocation after arecoline treatment.
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